TG Therapeutics (NASDAQ:TGTX) Trading Up 4.8%

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report)'s stock price was up 4.8% on Thursday . The company traded as high as $14.63 and last traded at $14.48. Approximately 1,638,056 shares were traded during trading, a decline of 61% from the average daily volume of 4,168,954 shares. The stock had previously closed at $13.82.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on TGTX shares. JPMorgan Chase & Co. reaffirmed an "overweight" rating and set a $25.00 price target on shares of TG Therapeutics in a research note on Thursday. StockNews.com cut shares of TG Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, February 24th. The Goldman Sachs Group increased their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Thursday, February 29th. LADENBURG THALM/SH SH reissued a "buy" rating and issued a $39.00 price objective on shares of TG Therapeutics in a research note on Thursday. Finally, B. Riley increased their price objective on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $29.00.

TG Therapeutics Stock Performance

The firm has a market capitalization of $2.16 billion, a PE ratio of 699.85 and a beta of 2.30. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. The company's fifty day moving average price is $15.13 and its two-hundred day moving average price is $13.87.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.03. The business had revenue of $43.97 million for the quarter, compared to analyst estimates of $40.06 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. During the same period in the prior year, the firm posted ($0.39) EPS. As a group, equities analysts expect that TG Therapeutics, Inc. will post -0.12 earnings per share for the current year.

Insider Activity at TG Therapeutics

In related news, Director Laurence N. Charney sold 22,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the transaction, the director now owns 215,229 shares in the company, valued at $3,437,207.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 9.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in TG Therapeutics by 13.3% in the third quarter. Vanguard Group Inc. now owns 14,746,392 shares of the biopharmaceutical company's stock valued at $87,299,000 after buying an additional 1,725,560 shares during the period. State Street Corp grew its position in TG Therapeutics by 47.8% in the second quarter. State Street Corp now owns 14,235,263 shares of the biopharmaceutical company's stock valued at $60,500,000 after acquiring an additional 4,606,679 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in TG Therapeutics in the first quarter valued at approximately $157,187,000. BlackRock Inc. grew its position in TG Therapeutics by 12.1% in the second quarter. BlackRock Inc. now owns 9,917,463 shares of the biopharmaceutical company's stock valued at $246,350,000 after acquiring an additional 1,067,763 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in TG Therapeutics by 1.4% in the fourth quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company's stock valued at $53,627,000 after acquiring an additional 43,290 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.